Literature DB >> 22158347

Industry continues dabbling with open innovation models.

Cormac Sheridan.   

Abstract

Mesh：

Year:  2011        PMID： 22158347     DOI： 10.1038/nbt1211-1063a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Pfizer reaches out to academia--again.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

2.  The protozoan inositol phosphorylceramide synthase: a novel drug target that defines a new class of sphingolipid synthase.

Authors:  Paul W Denny; Hosam Shams-Eldin; Helen P Price; Deborah F Smith; Ralph T Schwarz
Journal:  J Biol Chem       Date:  2006-07-22       Impact factor: 5.157
  2 in total
  2 in total

1.  Can Drug Repositioning Work as a Systematical Business Model?

Authors:  Jianan Huang
Journal:  ACS Med Chem Lett       Date:  2020-04-17       Impact factor: 4.345

Review 2.  Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.

Authors:  John G M Mina; P W Denny
Journal:  Parasitology       Date:  2017-06-22       Impact factor: 3.234
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.